





The South East Asia region of WHO alone accounts for 60% of all Tuberculosis cases in the world. It also has second largest number of people infected with HIV. The region has largest number of notified MDR-TB cases and an even larger population harboring drug resistant tuberculosis yet to be diagnosed. Most of the member countries in the South East Asia region are developing countries. The convergence of dual epidemic of HIV and MDR-TB can lead to a whole new epidemic. The issues with drug resistant TB and HIV are that little or nothing is known about effective diagnosis, treatment and prevention of co-infection. The public health significance of co-infection is even higher as the treatment of the co-infection is very difficult long and not well tolerated. The co-infection in absence of treatment is almost always fatal. Little or nothing is known about the appropriate regimen to treat the co-infection. The treatment regimens that are currently recommended by WHO are mostly based on small cohort studies. The interaction of second-line anti TB drugs and anti-retroviral therapy at population level is unknown. 
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Tuberculosis (TB) is one of the oldest diseases known to mankind with documented evidence of infections found in Egyptian mummies (1). The disease has terrorized humanity for over five millennia. TB is caused by mycobacterium tuberculosis. It is the second leading infectious disease as a cause of death next to Human Immunodeficiency virus (HIV)/Acquired Immunodeficiency syndrome (AIDS) (2).  Tuberculosis is still a major problem in developing countries with a large number of new patients every year and millions of deaths every year. According to World Health Organization (WHO) in 2011 alone 8.7 million people fell ill with TB and 1.4 million deaths were reported due to TB (2). The economic burden due to the disease is also enormous with US $8 billion per year needed to maintain the existing health programs in low and middle income countries (2).
The world is facing newer problems in the control of Tuberculosis (TB) due to reactivation of latent tuberculosis in patients suffering from Human Immunodeficiency Virus (HIV) infection. One–third of 34 million patients suffering from HIV have latent TB and they are 20-30 times more prone to developing active TB (3). TB is one of the most common presenting symptoms in patients suffering from HIV (3). Tuberculosis is the leading cause of death amongst patients suffering from HIV and was responsible for 430,000 deaths in 2011(3). The interaction of TB and HIV is of further importance as there is growing evidence suggesting that HIV co-infection in TB patients may be a risk factor for development of MDR-TB or XDR-TB. The review of studies on HIV and MDR-TB conducted by Suchindran S. et al (5) indicated an association between HIV and MDR-TB. Although there is a large debate regarding the statistical significance of this relationship (5,6).
The current challenges are to understand the complications that will appear due to the interaction between HIV and drug resistant TB co-infections and to devise newer treatment regimens and supports for these patients in national programs. HIV and TB co-infection are difficult to deal, even when TB is easily treatable. The co-infection is further complicated if the strain of M. Tuberculosis is drug resistant (7-10). Effective treatment of MDR-TB/XDR-TB is complicated as these agents do not respond to the first-line drugs. The treatment can take up to 2 years with second-line drugs that are much more costly and toxic (9). The following review examines the co-infection of HIV and MDR-TB/XDR-TB and discusses the epidemiology and treatment issues related with HIV and MDR/XDR-TB. The review closes with an examination of impact of HIV and MDR/XDR-TB in the South East Asia region of WHO. The member states of the South East Asia region are Bangladesh, Bhutan, Democratic People's Republic of Korea, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand, Timor-Leste. 

2.0 	APPROACH
A literature of the topic area review was conducted. In this review relevant publications were identified through the pubmed publication database. Using the search term “drug resistant tuberculosis” the search identified 8689 articles. A refinement of this search was made using combined search terms of ‘Drug resistant Tuberculosis’, ‘HIV’ and ‘Treatment’, which generated 1304 results. Further the number of identified publications went down to 147 reports after adding the word “Asia” to the search. A synonym for treatment, “therapy” was used to cover any articles that might be missed. This search generated 1175 articles with the key words drug resistant TB, HIV and Therapy. Further the number of articles identified went down to 97 after adding the word Asia. A separate search was also made using MDR-TB as a search term instead of drug resistant TB to cover any articles that might be missed on the previous searches. The combination of words ‘MDR-TB’, ‘HIV’ and ‘Treatment’ was used and generated 343 results, which were narrowed down to 66 articles after adding ‘Asia’ to the search. A search was also conducted using the word ‘Therapy’ in combination to MDR-TB and HIV, which generated 291 articles. The various combinations of MDR-TB, HIV and Therapy with individual member countries were also made to cover any missing articles from the list. The final list of publications for review comprised of 213 articles after deleting duplicate entries and irrelevant articles. The problem of MDR-TB and HIV is a fairly recent concern, so a large number of articles could not be found on the topic of treatment or management issues in MDR-TB and HIV co-infection. The purpose of this review is to cover all the articles that discuss the difficulties faced in treatment of MDR-TB and HIV co-infection. The final list generated by literature search was reviewed for relevant studies. The references in the relevant studies were further analyzed to find any relevant studies that might be overlooked in the process.
3.0 	Epidemiology of tuberculosis
This section will discuss the epidemiology of TB, TB and HIV co-infection, drug resistant TB, drug resistant TB and HIV co-infection and the burden of disease, globally and in South East Asia region of WHO.
Tuberculosis (TB) is a major health problem and is the second leading cause of death from infectious disease right after HIV (10). TB is caused by mycobacterium tuberculosis and is spread from infected person via airborne transmission (31). TB usually affect the lungs, but extra-pulmonary can affect any part of body namely kidneys, brain, intestine and spine. The infection most often does not progress to a full-blown disease and stays in a latent phase. It is estimated that one-third of the human population has latent tuberculosis. The infection can progress to tuberculosis disease if the immune system is not able to limit the bacterium. The outcome of TB disease if not treated is fatal (31). WHO estimated that there were 8.7 million cases of TB and 1.4 million deaths from TB in 2011 (2,10).The diagnosis of TB is done using sputum smear microscopy. Sputum smear microscopy requires trained personnel for slide preparation and diagnosis. The problem with sputum smear microscopy is that misdiagnosis is frequent (10). Recently WHO has been promoting use of rapid molecular tests for the diagnosis of TB (10).
Treatment strategies for TB frequently last 6-8 months long, and use the first-line antibiotic drugs namely isoniazid, rifampicin, pyrazinamide, ethambutol and streptomycin in combination. The intensive phase of the treatment lasts for 2 months and uses all five drugs. The continuation phase of the treatment can last between 4-6 months, and uses two or three of the first-line drugs. TB treatment is given under a Directly Observed Treatment Short course (DOTS) and has been implemented in most of the countries as a standard regimen for treatment of drug susceptible TB. This therapy has high treatment success rates (85%) if it is maintained. 
The BCG vaccine is the only available vaccine currently used to prevent TB. It protects against severe forms of TB like spinal TB and meningeal tuberculosis, but its efficacy in protection against pulmonary TB is highly variable (10). Newer Vaccines are being developed to prevent TB and are in developmental stages with few of them in Phase II trials (10). 
3.1	TUBERCULOSIS AND HIV
Recently the interaction of TB and HIV has gained a lot of attention at the global level. Tuberculosis is the leading cause of death in people infected with HIV and people with HIV associated TB have higher risk of mortality (3,22). The estimated number of deaths due to HIV associated TB was 430,000 in 2011 (3).
It is estimated that one-third of total population living with HIV is infected with latent TB. The person who has HIV has 20-35 times more chances of developing active TB after infection with M. Tuberculosis as compared to person who is HIV- negative (3,10). The HIV is a risk factor for progression of latent TB to TB disease (32). This is very likely   due to the immunosuppression associated with HIV in the patients.
 It is estimated that 1.1 million incident TB cases globally were HIV-positive in 2011 (3).  However, many cases of HIV and TB combined are not diagnosed. Therefore, WHO recommends HIV testing in all the patients with TB in areas with high HIV and TB burden and in 2011 40% of notified TB cases had documented HIV results amounting to 2.5 million cases (10).
 The early diagnosis is recommended due to fact that early initiation of ART in patients with HIV and TB substantially reduces morbidity and mortality (10). The treatment in patients with HIV and TB includes early initiation of anti-retroviral therapy (ART) along with anti-TB medication. ART is a combination of at least three antiretroviral drugs to suppress the viral load and achieve best results. Various antiretroviral combinations are possible but in general the regimen includes a nonnucleoside reverse transcriptase inhibitor (efavirenz or nevaripine) and two nucleoside reverse transcriptase inhibitors (10,22).
 WHO recommends initiation of ART as early as possible irrespective of CD4 counts in the patients with TB and HIV co-infection. The current recommendation as per WHO Global Tuberculosis Report, is to start ART within 2 weeks of initiation of TB treatment (10). The Co-trimoxazole preventive therapy (CPT) and isoniazid preventive therapies (IPT) are recommended by WHO in patients with TB and HIV co-infection. CPT is proven to reduce the symptoms and improve quality of life in HIV patients (33). IPT is effective in reducing the incidence of TB in HIV-positive individuals (33). The regimen is inexpensive and highly effective and so WHO recommends IPT to be given to all the patients suffering from HIV in areas with high prevalence of TB after active TB has been ruled out (3,10,22). Similarly WHO recommends that CPT should be started in all patients suffering from HIV and TB co-infection (3,10,22).

3.2	drug resistant tuberculosis
Drug resistant strains of Tuberculosis are the strains of M. Tuberculosis that are resistant to anti-TB drugs mostly to the first-line drugs. Multi drug resistant tuberculosis (MDR-TB) is caused by mycobacterium tuberculosis that are resistant to most effective anti-TB drugs like rifampicin and isoniazid. MDR-TB can be a result of infection by organism that is already drug resistant or an acquired resistance during the course of the patient’s treatment (4).  Extensively drug resistant tuberculosis (XDR-TB) is caused by mycobacterium tuberculosis that are resistant to isoniazid and rifampicin like MDR-TB, XDR-TB is also resistant to any of second-line drugs like floroquinolones and injectable anti-TB drugs like kanamycin, amikacin or capreomycin (4). MDR-TB and XDR-TB are becoming an important public health problem globally making the control of TB difficult due to their resistance to most first-line drugs.
 The risk factors associated with the development of MDR-TB/XDR-TB are previous TB treatment exposure, age, smoking, and HIV. Previous treatment for TB is a well-established risk factor for the development of MDR-TB/XDR-TB. While there are multiple mechanisms by which M. Tuberculosis can gain resistance, it was soon established that treatment of TB with a single drug would result in development of resistant strains (34). This observation is the reason for the current multi-drug regimen for TB (34). Anti-TB drug resistance is usually acquired through spontaneous mutation in M. Tuberculosis followed by selection due to poor drug regimens, poor drug supply or poor adherence (34). The resistant strains then are propagated due to delayed diagnosis and improper treatment.
 Data collected from surveillance systems show a very strong association between past treatment history and ongoing treatment and MDR-TB and XDR-TB.  Reports from 17 countries collecting continuous surveillance  data showed that proportion of MDR-TB in new cases was 1.5% (95% CI: 0.5-2.6) and among relapse cases was 7.9% (95% CI: 2.9-12.9) (9). A survey conducted by Skrahina A. et al showed a high association between past treatment with anti-TB medication and drug resistance with the odds of resistance being much higher in previously treated cases as compared to those with no history of previous treatment (OR = 6.1, 95% CI= 4.8-7.7) (7). Similar results were published in the fourth global report on anti-TB drug resistance in the world (8).
 Globally there is no difference in the rates of drug resistant TB among men and women (10). The study conducted by Skrahina A. et al also showed higher prevalence of MDR-TB in patients with age < 35 years. The same study also found an association between smoking and drug resistant TB, with odds of MDR-TB being 1.5 times higher in smokers as compared to non-smokers (7). The explanation of how smoking increases risk of drug resistant TB is unclear. One possible explanation was that smokers are more likely to make poor decision regarding their health leading to non-adherence to treatment.
World Health Organization (WHO) provides incidence and prevalence data on MDR-TB. This data is collected by WHO’s member states and reported annually through the National programs for the control of TB. Overtime there has been constant improvement in the collection and reporting of drug resistance data with almost 70% (135 countries) of WHO’s member states making data available on the MDR-TB (10). The updated data for 2012 is available from 27 states considered as high burden for MDR-TB (9, 10).
 The estimated number of people suffering from MDR-TB globally is 3.7% in new cases and 20% in previously treated cases (10). WHO estimates in year 2011 for new cases of MDR-TB was 0.5 million worldwide.  Figure 1 shows all the countries that have at least one case of MDR-TB reported till 2012. The estimated number of MDR-TB cases in different WHO regions in 2008 is shown in Table 1. Almost 60% of these cases are seen in China, India, Russian Federation, Brazil and South Africa (4, 10). China and India alone account for almost 50% of the new cases of MDR-TB (9, 10). 
Figure 2 shows the proportion of cases of MDR-TB who were enrolled on treatment in 2011 compared to the estimated number of cases in the country.  Figure 2 includes all the countries that have estimated number of cases of MDR-TB higher than 1000.The figure highlights substantial difference by country in treatment of MDR-TB.
One reason for treatment difference by country may be that the treatment for MDR-TB is much more complicated than the treatment for drug susceptible TB. The standard recommended treatment for MDR-TB is for at least 20 months using second-line drugs like floroquinolones, PAS, cycloserine, ethionamide, kanamycin etc (9,10,22). The specific treatment regimen depends on the drug susceptibility testing results of the individual patients with different types of regimens being advised for different types of resistance, depending on which the final regimen has to be decided (10,17,18). 





Table 1. Estimated number of MDR-TB cases (primary and acquired) in 2008, by WHO region
WHO region	Estimated number of MDR-TB cases(primary and acquired) in 2008 (95% confidence interval)
African	69 000 (53 000–110 000)
Americas	8 200 (7 300–9 300)
Eastern Mediterranean	24 000 (11 000–81 000)
European	81 000 (73 000–90 000)
South-East Asi	130 000 (110 000–170 000)
Western Pacific	120 000 (100 000–140 000)





Figure 1.WHO member states with at least 1 reported case of MDR-TB in 2012





Figure 2. Proportion of MDR-TB subjects receiving treatment, 2011.





3.3	DRUG RESISTANT TUBERCULOSIS AND HIV
The emergence of MDR-TB and XDR-TB has raised a significant concern among global health officials. The combination of MDR-TB/XDR-TB and HIV expands this concern substantially However, the biggest issue with the co-infection of MDR-TB/XDR-TB and HIV is that there is not enough epidemiological data collected on an international level to determine the actual burden of the problem.  Data on drug resistant TB and HIV co-infection exists exists only from various studies and surveys carried out in scattered regions around the world (9, 10). Limited data is available on the association of HIV and drug resistant TB at population level (8-10). Thus the real magnitude of issue is not known.
 Special attention has been paid to the co-infection in recent years due to sudden increased evidence showing association between HIV and MDR-TB. There are numerous studies showing an association between HIV co-infection and drug resistant tuberculosis. The study by Shkrina A. et al showed positive association between HIV infection and MDR-TB with odds of being diagnosed MDR-TB were 2.2 (95% CI 1.4-3.5) times in HIV-positive patients as compared to HIV-negative patients suffering from tuberculosis. (7). The review of studies on HIV and MDR-TB conducted by Suchindran S. et al and study conducted in Eastern Europe came to same conclusion (5, 6). Thus HIV infection is a risk factor for development MDR-TB.
 Mortality in MDR-TB patients who are HIV-positive is also much higher than MDR-TB patients who are not HIV-positive. MDR-TB and HIV co-infection has been a documented cause of higher mortality in treatment cohorts and in outbreaks in the population (8,12,13). The mortality rates in co-infection of MDR-TB and HIV are higher compared to patients suffering from HIV and drug sensitive TB and patients suffering from only MDR-TB infection (14-16). A study conducted in New York City  found much higher mortality in HIV-positive patients with MDR-TB (60%) as compared to HIV-positive patients with drug sensitive TB (26%) (15). 
The impact of combination of HIV and MDR-TB goes beyond mortality and includes large differences in treatment outcomes as well. A study in Latvia showed similar results where 44% of patients with MDR-TB and HIV had poor treatment outcomes like default, failure and death compared to 27% of the HIV-positive patients with drug sensitive TB (14, 15). Another study found that HIV infection increased the risk of poor treatment outcome 10-fold (OR 10.16, 95% CI: 1.17–88.84) in patients suffering from MDR-TB (16).
Additional issues concerning the co-infection of HIV and MDR-TB are difficulty in diagnosis and treatment of the cases. The limited laboratory capacity for diagnosis of susceptibility to first and second-line anti-TB drugs makes early cases detection difficult. Drug susceptibility test take at least 4-6 weeks of time depending on the setting and proximity to testing centers. The lack of standard testing regimens for second-line anti-TB drug susceptibility make the issue more complicated. The lack of data on interaction between second-line anti-TB medication and antiretroviral drugs is a major drawback. There is no standard treatment regimen for treatment of MDR-TB and HIV co-infection which has been proven highly effective leading to increased difficulty in management of patients (22).

3.4	Tuberculosis, DRUG RESISTANT TUBERCULOSIS, HIV and drug resistant Tb and HIV co-infection IN SOUTH EAST ASIA
The South-East Asia designated by WHO includes Bangladesh, Bhutan, Democratic People's Republic of Korea, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor-Leste. The South-East Asia region combined with Western Pacific region account for 60% of the TB cases in the world (10). The estimated incidence of TB cases in South East Asia region alone in 2011 was 189,000 (95% CI: 176,000 – 203,000) cases (10). The estimated prevalence of TB in South-East Asia in 2011 was 271,000 (95% CI: 206,000-344,000) cases. Tuberculosis was responsible for 26,000 (95% CI: 19,000- 34,000) deaths in South East Asia region (10). Thus the region has a significant burden of the TB and a lot of government and private funding is directed towards management of TB in the region. 
The region is also home to 4 million HIV cases, second only to sub-Saharan Africa in the total number of HIV cases (10). The incidence of HIV in the region in 2011 was 211,000 new cases (35). The estimated number of HIV related deaths in the region was 230,000 in 2011(35). The countries with maximum burden of HIV are India, Indonesia, Myanmar, Nepal and Thailand. These countries also have high burden of TB in the region (10,35). It is not surprising that the estimated incidence of HIV-positive TB cases in 2011 was 140,000 (35). India, Myanmar and Thailand have high TB-fatality rates and also high prevalence of HIV (35). 
The estimated incidence of MDR-TB cases in South-East Asia in 2011 was 89,000 (72,000-108,000) (35). This accounts for one-fourth of the total number of MDR-TB cases globally amongst the notified MDR-TB cases (10,35). This estimate depends on Drug Resistance Survey conducted by national programs and might be an underestimate of the problem in the region. India has the highest number of MDR-TB patient amongst notified TB patients (10).  Figure 3 shows the comparison of cases of TB reported vs. the cases of MDR-TB reported under the national programs in the region. It can be seen that there is a study rise in the number of reported cases in the region with only 68 cases reported in 2006 compared to 6,615 cases in 2011. The DST testing in the region is low with only 4% of newly diagnosed cases being tested for drug resistance. It can be seen from Figure 2 that the proportion of MDR-TB cases enrolled in treatment in the member countries of the region like India, Thailand and DPR Korea is as low as 1%-6%. The highest number of cases MDR-TB were estimated to be in India (79000-120000) and lowest number of cases was seen in Maldives (0-6) in 2008 (8). 




Figure 3. WHO South East Asia region Reported cases of TB vs. Reported cases of MDR-TB 2006-2011
Image obtained from https://extranet.who.int/sree/Reports?op=vs&path=/WHO_HQ_Reports/G2/PROD/EXT/MDRTB_Indicators_charts (​https:​/​​/​extranet.who.int​/​sree​/​Reports?op=vs&path=​/​WHO_HQ_Reports​/​G2​/​PROD​/​EXT​/​MDRTB_Indicators_charts​)

4.0 	treatment challenges in south-east asia region
The extensive review of the literature generated only a handful of articles describing the public health issue of MDR-TB and HIV co-infection in South-East Asia. Few of the articles identify the epidemiology and treatment challenges of MDR-TB and HIV co-infection observed in region. Most of the available studies focus on the outcomes and the adverse events that were observed in a cohort of HIV patients infected with MDR-TB. (17,18,21). A study on prevalence of anti-TB drug resistance patterns in HIV-positive patients in South India is identified (19), as were two studies from Thailand describing the issues of HIV, TB and MDR-TB in border region with  (20). 
 Resistance to First line drugs: 
Many issues afftect the  treatment due to co-infection of MDR-TB and HIV, including a varied level of resistance to first line drugs, adverse events due to treatment, treatment outcomes, quality of life of the patients. The resistance to first line drugs for treatment of TB is a major issue in HIV and MDR-TB co-infection. A study in India by Swaminathan et al. had 204 patients with HIV-positive status in whom M. Tuberculosis was isolated from a sputum specimen. The study had 167 new cases of TB (no prior treatment or < 1 month of TB treatment in the past) and 37 cases had previous treatment of >1 month. The prevalence of drug resistance observed to first line drugs in the study in patients with no prior history of treatment was 15.6%. The prevalence of resistance to first line drugs in previously treated patients was 37.8%. The study observed MDR-TB in 7 (4.2%) of 167 new cases whereas the percentage was much higher in previously treated cases with 5 cases infected with diagnosed of MDR-TB (13.5%) (19).
 Kittikraisak et al. in their study regarding the prevalence TB, HIV associated with TB and MDR-TB on Thailand’s border with Myanmar observed drug resistant patterns in 304 patients (18%) of the total registered patients. The number of patients with MDR-TB was 6 (2%) of the 257 patients who had no history of previous treatment. The number of patients with MDR-TB in previously treated patients was 21 (45%), much higher than those with no treatment. The study found that of the 27 MDR-TB cases, only 2 (7%) were HIV-positive, 18 (67%) where HIV-negative and 7 (26%) had unknown HIV status. Of the 27 MDR-TB patients, 19 were non-Thai (21). 
A study conducted by Isaakidis et al.  analyzed 67 patients with MDR-TB and HIV co-infection in Mumbai, India. The cohort had only 5 patients with no history of previous treatment. There were 3 patients in the cohort who were diagnosed with XDR-TB. The patients had previous history of treatment from either the private or the public sector and half of the patients in the cohort had previous history of treatment with second-line anti-TB drugs. This study also describes clearly the duration of ART for each of the patients (17,18).




The study by Isaakidis et al. on a cohort of 67 patients with HIV and MDR-TB co-infection done in Mumbai, India describes the adverse events observed in the small cohort of patients treated on second line anti-TB drugs and anti-retroviral drugs (ART) simultaneously (17,18). The combination of second line anti-TB drugs and ART was of concern due to additive toxicity of the medications. Particularly, the co-administration of tenofovir with aminoglycoside and capreomycin, and their additive renal toxicity was of concern. Similarly additive psychiatric toxicity of efavirenz and cycloserine and increased risk of peripheral neuropathy due to administration of stavudine and ethionamide can exist. 
The study period was from May 2007 to September 2011 and during this time period 67 patients where observed and then further analyzed. The patients were evaluated by a multi-disciplinary team of trained physicians and nurses, at baseline and throughout the study. The adverse events observed during the study were gastrointestinal symptoms, peripheral neuropathy, hypothyroidism, psychiatric adverse events and hypokalemia. The study did not report any adverse events due to drug induced hepatitis. Adverse events were pre-defined as per clinic protocol and criteria for severity and treatment for each of the adverse events is described in the study. Most of the adverse events in the study occurred within 2-4 months of initiation of the anti-TB treatment. The median number of adverse events experienced by patients was 2 (range 1-6). Overall one or more mild adverse events were observed in 71% of the patients. Sixty three percent observed moderate adverse events and 40% observed severe adverse events. Patients could experience more than one episode of an adverse event and the most severe one was finally used for analysis. 
Gastrointestinal adverse events were the most common and occurred in nearly 50% of the patients in the study. The median duration of the GI adverse events was about nine weeks from the start of anti-TB drugs. Peripheral neuropathy was observed amongst 37% of the patients with eight patients suffering from severe neuropathy. One third of the patients in the cohort experienced psychiatric disturbances which were mostly due to Cycloserine and/or Efavirenz. These drugs had to be discontinued from the treatment regimen due to severe psychiatric symptoms in eight patients. Hypokalemia was seen in 22% patients after a median duration of 16 weeks treatment. 
A total of 11 patients were hospitalized due to serious adverse events like severe renal impairment, hypokalemia, seizures or severe psychiatric symptoms. The outcome of hospitalization in patients was favorable with only 3 deaths during hospitalization. The adverse events were managed symptomatically and discontinuation of medication was made only if the adverse event was life threatening. The adverse events were tackled by rapid symptomatic treatment and discontinuation of the offending drug until the signs and symptoms and/or the laboratory tests improved. 
The biggest issue was finding an alternative for the second line drug in most of the patients who had to be taken off the drug due to adverse events. The participants were already on second-line anti TB drugs for which no alternatives were available. The drugs were discontinued in case of a severe adverse event.  Offending drugs were only discontinued temporarily where ever possible and reintroduced later on as the condition of the subject improved. The most common drugs that were discontinued permanently due to an adverse event were Para-aminosalicylic acid (PAS) and Cycloserine. Twenty-seven patients required permanent discontinuation of at least one drug. There was no occurrence of discontinuation of the entire MDR-TB regimen or antiretroviral therapy in the study. The final analysis study did not show any significant association between a severe adverse event and unfavorable outcome on univariate analysis (OR = 1.12, 95% CI: 0.41-3.07) (18). 
Treatment outcomes:
The study conducted by Iskaadis et al. describes the treatment outcome in a cohort of the patients with MDR-TB and HIV co-infection. The study included 71 patients diagnosed with MDR-TB and HIV co-infection starting from May 2007 till April 2011. Of these patients, 12 never started MDR-TB treatment. Seven out of the twelve patients died before the initiation of treatment, 2 refused the treatment after counseling, one patient was lost to follow-up and for two patients second-line treatment was not indicated as one improved on first line drugs before DST reports came in and the second one was only susceptible to PAS, so no other option of treatment was available except palliative care. The remaining 59 patients were all started on second line anti-TB medication. The treatment in each patient was continued for a minimum of 6 months of intensive phase followed by 12 months of continuation phase leading to 18 months of total treatment. 
The treatment outcomes in the patients on the regimen at the end of the observation period were as follows: 14% (8 patients) were cured, five (9%) of the patients completed the treatment, 13 patients (22%) died, 2 patients (3%) failed treatment, 7 patients (12%) defaulted and 23 patients (40%) were alive and in treatment at the end of the observation period. Sputum conversion was seen in 52% of the patients with positive smear at the baseline by 2-4 months of treatment and they were not infective after intensive phase. Similar conversion rates were seen in culture specimen after 4 months of treatment. 
The 13 patients who died had a median survival time of 27 days (range1-299 days) after initiation of treatment. The cause of death was unrelated to TB in four patients out of the total 13 deaths. The probability of survival observed in the study after 24 months of treatment was 0.75.
 The 7 patients who defaulted had the following characteristics: one patient was a Nepalese immigrant who decided to repatriate, one patient had a problem in accessing the clinic and one patient refused to continue treatment after 15 months. Two patients who were suffering from XDR-TB were lost to follow-up and two more patients discontinued the treatment without any apparent reason.  The study observed that patients who were susceptible to fluoquinolones were less likely to default than the patient who were resistant to fluoquinolones (p<0.05). All except 3 patients who were on MDR-TB treatment also received ART as per protocol (17). 
Health Related Quality of Life:
Krittikraisak et al. collected health utility data from patients who were being treated for TB or had been successfully treated for TB. The health related quality of life (HRQL) data are important in a case of TB as the duration of treatment is 6 or more months. The treatment protocol isalso much more complicated in presence of HIV infection or in the case of Drug resistant TB where the treatment duration is much longer. The study analyzed HRQL using the Euro Qol 5D (EQ-5D) and Euro Qol visual analogue scale (EQ-VAS) measures in Thai patients who were currently undergoing treatment or had completed the treatment. 
The study only had one patient with MDR-TB and HIV co-infection and so the patient was not used in final analysis. Still the results from the study are important as it is the first study that uses recommended and valid instruments to measure HRQL in the Thai population. The study observed that the HRQL of patients with MDR-TB was worse than any other group included in the study. One of eight patients suffering from MDR-TB perceived his overall health to be worse than death (EQ-5D, -0.02). The patient had been diagnosed and was undergoing treatment for 26 months. The study also observed that the overall median EQ-5D scores were highest amongst patients with any kind of TB who were cured (1.0, IQR: 0.7-1.0) and lowest amongst MDR-TB patients undergoing treatment (0.5, IQR: 0.6-0.8). Similar results were observed on health utility measures using the EQ-VAS instrument. The MDR-TB patient with EQ-5D score of -0.02 rated his condition equivalent to death on EQ-VAS. It was also seen that EQ-VAS was higher in all groups except for the group being treated for MDR-TB (21).

5.0 	DISCUSSION
The increased risk of MDR-TB and XDR-TB in patients with HIV has been identified from numerous studies (4-8,22-24). Despite the findings, little or no attention has been directed towards MDR-TB and HIV co-infection (22,23). We realize after looking at the review of literature that there is lack of research on this topic in the South-East Asia region. The studies also point out the lack of research that examines treatment issues with MDR-TB and HIV co-infection (16-20).
 Important aspects in the management of co-infected individuals apart from treatment are prevention, screening and diagnosis of MDR-TB. The early diagnosis of MDR-TB in co-infected individuals is very important. The lack of early diagnosis of MDR-TB in co-infected patients has been attributed to high mortality by WHO (9,22). The diagnosis of MDR-TB relies on sputum sensitivity and Drug Susceptibility Testing (DST) which are time consuming. The new guidelines by WHO of implementing rapid molecular diagnostic techniques and strengthening the laboratory networks of individual countries under EXPAND-TB project will play a crucial role in the resolution of the issue. The latest endorsement of Xpert MTB/RIF as a rapid molecular test for diagnosis of MDR-TB will also improve diagnosis and surveillance (9,10,22). Thus early diagnosis and early initiation of treatment may reduce the mortality rates in patients with co-infection. The widespread use of Xpert MTB/RIF in the South East Asia region would lead to a much rapid diagnosis of MDR-TB. This would lead to easy identification of actual prevalence of problem in the region as the national programs would not have to rely on limited laboratories available for the drug susceptibility testing in the region. 
The issue of resistance to first line drugs is also highly important in treatment of patients suffering from drug resistant TB and HIV. The WHO recommends duration of treatment for patients who are suffering from drug sensitive TB to be usually 6-8 months. This includes the use of the first line drugs namely Rifampicin, Ethambutol, Isoniazid, Pyrizinamide and Streptomycin (10). The recommended treatment by WHO for MDR-TB with second line drugs is a minimum of 18 months, but WHO recommends 20 months of treatment in most cases with a regimen that includes second-line drugs.
 Even though treatment options are available for MDR-TB, there are numerous problems associated with the treatment regimen. The longer duration of treatment leads to more chances of failure, default and increased cases of resistance to second-line drugs. The proper time of initiation of ART is also not established, but a lot of studies show that the earlier initiation of ART leads to better outcomes (17,18). The fact that little is known about optimal regimen and duration of treatment with second-line anti-TB drugs in MDR-TB and HIV co-infection also complicates the issue (22).
The number of studies about the interaction between second-line anti-TB drugs and ART in an ambulatory setting is limited (17,18,22,27,28). The second-line drugs are not as effective as first line drug against M. Tuberculosis. They are associated with multiple side effects and lower cure rates. Also there is the interaction with ART in co-infected patients which leads to higher side effects (10). The evidence of increased adverse events of first-line drugs in HIV-positive patients is shown, but no such evidence is present for second-line drugs (30). The study by Isaakidis et al. showed numerous life threatening adverse events observed in MDR-TB and HIV co-infected patients (17,18). Similar results are seen in other studies conducted all over the world. One systemic review conducted showed more adverse events in patients on second-line anti-TB and ART (14). The adverse events are higher with co-infection as compared to MDR-TB infection alone (29). Thus much higher side effects are seen with second-line anti-TB drugs and ART which might make the treatment difficult. The interaction between second-line anti-TB drugs and ART needs to be studied and optimization of treatment of MDR-TB and HIV co-infection is necessary with much research is warranted on the topic (22).   
WHO, in its recent report on TB, has provided estimates of mortality due to MDR-TB which are much higher as compared to drug resistant TB but have excluded the impact of HIV co-infection on mortality from analysis due to lack of proper data (9,10). The treatment outcomes in MDR-TB and HIV co-infection are also much less favorable then then seen in just MDR-TB infection or drug sensitive TB and HIV co-infection alone (14,15). The mortality rate is much higher in patients with MDR-TB and HIV co-infection as seen in a systemic review on Multi-drug resistant TB treatment regimens (25). The mortality rates are much higher in the subgroup if the treatment is not instituted early (9). The mortality rates are higher where there is resistance to floroquinolones in patients with co-infection (10,16-18). The mortality is much higher with extremely drug resistant and HIV co-infection (12). 
The default and failure rate are also different in patients seen with MDR-TB and HIV co-infection as compared to other sub groups. The patients suffering from HIV and MDR-TB have much higher rate of defaults as compared to patients with MDR-TB who were HIV-negative (26). Similar results were seen in failure of treatment with higher failure seen in patients with co-infection (26). The treatment duration is also longer in patients who have co-infection compared to patients who are just infected with MDR-TB (26). Thus even though better outcome rates are seen in South-East Asia region they are not indicative as the study population is small and more studies would be needed. The longer duration of treatment in MDR-TB and HIV co-infection may also lead to effect on the perception of health related quality of life of the patient. The adverse events associated with second-line anti-TB medication and ART are much higher and so the patients might have much lesser perception of HRQL. This might be responsible for higher default rates seen in the patients.
The treatment of MDR-TB and HIV co-infection is more expensive and is responsible for substantial burden on  National Programs (9,10,22). The higher treatment cost can be attributed to second-line drugs that are much costlier than the first line drugs and also to the longer duration of treatment in case of MDR-TB and HIV co-infection. According to 2012 WHO estimates patients with MDR-TB have an average cost of US$ 200-800 associated with treatment and this is not considering the cost of ART. The cost of treating a patient with drug susceptible TB with HIV co-infection is US$100-365 (10). Most second-line drugs are not freely available in the public sector in a lot of countries and thus the cost can be substantially higher. This might result in unnecessary burden on the patients (17,18). The treatment of MDR-TB was not available in public sector in India before 2010 (18).Thus, we currently need drugs that are highly active against MDR-TB and reduce the treatment duration to bring down the financial burden associated with the treatment of co-infection. 
The treatment of co-infection is going to put major burden on the national programs in the South-East Asia region. The major burden in South East Asia region is concentrated in India, Indonesia and Myanmar. These countries are all low income and middle income countries. The WHO estimates for financing the current activities by National Programs in Low and Middle income countries is US$8 billion every year (10). The estimated funding gap for these activities for 2013 is US$3 billion (10). This combined with increased number of MDR-TB cases reported every year in the South East Asia region and WHO’s push to increase TB/ HIV collaborative activity will put a major financial burden on National programs globally. 
Countries in the South East Asia region will need support from external funding to scale up the laboratory and to maintain constant supply of the second-line anti-TB medication. WHO has put optimization of MDR-TB and HIV co-infection treatment regimen at the top of the list of priority research questions for control of TB and HIV (22). This is done to reduce the individual cost of the treatment of MDR-TB and reduce the financial burden on the high burden countries.
The individual burden of HIV and MDR-TB in the South East Asia region as seen from the data is huge. The two epidemics are slowly interacting in the region. There is limited data on how the infections are interacting with each other on a population level globally. But looking at results from various cohort studies it can be estimated that in a couple of years the co-infection of MDR-TB and HIV is going to be a big issue for the region. The factors that contribute to the assumptions are a huge private health care sector which was treating most of the drug resistant TB cases in the region. The public sector did not provide second-line drugs till 2010 (10). The treatment regimens in private sector are haphazard and this can lead to aggravated resistance to anti-TB drugs. This combined with slowly increasing number of HIV cases in the region has created a dual epidemic which is yet to be detected. The lack of data about the combined MDR-TB and HIV status limits our estimation of problem in the future but looking at the example of former Soviet Union and Peru we can safely assume to see similar patterns in South East Asia region. The recent establishment of Green Light Committee in 2012 will ensure intensified case detection and adequate provision of treatment for MDR-TB. 
In conclusion it is widely identified in the scientific community and by World Health Organization that the problem of the co-infection of MDR-TB and HIV is a major issue. The issue is further complicated by lack of quick diagnostic techniques, effective preventive and treatment strategies. The surveillance of the co-infection is still rudimentary and it is highly necessary that WHO member states provide continuous surveillance data on MDR-TB and HIV co-infection. The continuous surveillance is highly necessary to understand the impact of co-infection on a population level. The review identified numerous gaps in the knowledge about the treatment of co-infection. The lack of proper treatment regimen is for the co-infection is one of the major obstacles in the treatment of MDR-TB and HIV co-infection. There is no consensus on when to start the ART in the patients suffering from co-infection. The adverse events arising due to interaction of second-line TB and ART are not well-known. The treatment outcomes are drastically different as observed from different studies all over the world. WHO in its recent report on the control of TB has clearly identified all the gaps and has warranted a need to fill these gaps to achieve its goal of STOP-TB 2015. Thus further research is needed to answer all the unanswered questions on the issue of HIV and MDR-TB.
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